Latest News

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)-- #T1D--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on July 29, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares of its common stock to 4 new employees under Xeris’ Inducement Equity Plan. Xeris’ Inducement Equity

Source link

Related posts

Researchers discover underlying cause of hereditary muscle disease


STAT Plus: Up and down the ladder: The latest comings and goings


Deals, program launches headline digital health payer news during Q2 2019


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy